EU projects

The project is implemented under Sub-Activity ‘Promoting high value-added direct

foreign investments (HVA DFI): implementation of R&D, cooperation and technology

transfer between large enterprises and SMEs in the technology and innovation areas

(Central and Western Lithuania)‘ of Activity ‘Promoting attraction of direct foreign

investments in R&D under Progress Measure No 05-001-01-05-07 ‘Establishing a

Coherent System for the Promotion of Innovative Activities’ under the Economic

Transformation and Competitiveness Development Programme for 2022–2030 managed

by the Ministry of the Economy and Innovation of the Republic of Lithuania.

The project aims to upgrade UAB Imunodiagnostika‘s IVD medical device “Dried blood

microsampler” by improving the composition of the polymeric sample absorption tip

and introducing hemoglobin binding functionality.

Project budget 1 364 325,75 EUR (EU funding 818 595,46 EUR). Project duration

27/06/2024 – 27/06/2026. Project is implemented by Imunodiagnostika with partner

Polymer Competence Center. Project funding agency Innovation Agency Lithuania

(project No. 02-020-K-0066).

EUREKA project "New tools for the detection of antimicrobial resistance by immunological methods", project No 01.2.2-MITA-K-702-05-0003

The project is funded by the Agency for Science, Innovation and Technology/Lithuanian Research Council.

Project promoters: Vilnius University (coordinator), UAB Imunodiagnostika (Lithuania), ArcDia International Oy Ltd (Finland)

Project leader: Aurelija Žvirblienė (VU Life Sciences Centre).

Project duration: from 2020-03-01 to 2023-02-28.

The aim of the project is to develop novel monoclonal and recombinant antibodies against bacterial enzymes that determine antibiotic resistance and to evaluate the potential of these antibodies for the development of rapid diagnostic tests for antimicrobial resistance. The project is being carried out in several steps: (1) the selection of diagnostic targets - β-lactamases - based on relevance and importance; (2) the synthesis of these enzymes in E. coli expression system and purified; (3) monoclonal and recombinant antibodies specific for these enzymes are developed; (4) antibodies are characterised in detail and their ability to recognise targets in bacterial lysates is assessed; (5) antibodies with the best properties are selected and diagnostic systems are developed on the basis of them. Antibodies are being developed at the Immunology Department of VU GMC, project partner UAB Immunodiagnostika is contributing to antibody characterisation, and ArcDia International Oy Ltd, a Finnish company developing and manufacturing diagnostic tests, is assessing the diagnostic and commercial potential of the antibodies by testing biological samples on its proprietary TPX platform.

The result: molecular tools for the development of rapid diagnostic tests: antibodies against the β-lactamases involved in bacterial resistance to antibiotics.

UAB "Imunodiagnostika" has implemented the project "Development of recombinant allergen producers", Nr. 01.2.1-MITA-T-851-02-0218 financed by the European Regional Development Fund (project budget - EUR 46 826).

The aim of the project is to develop recombinant protein expression technologies by genetic engineering methods for the development of tools relevant to allergy diagnostics.

The recombinant allergen producers synthesising the biotechnological products to be developed in this project will have a high diagnostic value, i.e. they will improve the sensitivity and specificity of diagnostic tests.

UAB "Imunodiagnostika" is implementing the project "UAB "Imunodiagnostika" investments in R&D activities related to COVID-19", No 01.2.1-LVPA-T-858-01-0003 financed by the European Regional Development Fund. Funded as part of the European Union's response to the COVID-19 pandemic (project budget: EUR 582.094,59, allocated funding: EUR 465.675,67).

The aim of the project is to develop a globally innovative hybrid testing system for the detection of antibodies specific for COVID-19 and other cold viruses.

The successful implementation of R&D activities will lead to the development of a new multifunctional ELISA test that will be easily applicable in all hospital laboratories as they already have the necessary equipment. High-sensitivity tests will also be developed to check the response to several viral antigens at once, which will improve the accuracy of the test.

UAB Imunodiagnostika implements the project UAB Imunodiagnostika's investments in the production of diagnostic tests, No. 03.3.1-LVPA-T-859-0026, financed by the European Regional Development Fund (project budget - € 769,298.14, funding allocated - € 730,833.23). €).

The aim of the project is to develop an appropriate infrastructure for the production of diagnostic tests for the detection of COVID-19 specific IgG and IgM class antibodies.

The project will aim to create an infrastructure for the cultivation and isolation of test protein producers from yeast and tissue cultures. In addition to the standard equipment required for solution production and storage of blanks, a semi-automatic solution packaging line is planned to be installed in the solution production unit in order to maximize the automation of the solution packaging process.

UAB "Imunodiagnostika" is implementing the project "Development of a personalised allergy diagnostic tool based on artificial intelligence", Nr. 13.1.1-LVPA-K-856-01-0017, financed by the European Regional Development Fund as an EU response to the COVID-19 pandemic (project budget - € 1.447.516,87, allocated funding - € 1.039.255,41). The aim of the project is to develop a globally innovative allergy diagnostic tool (personalised allergy diagnostic tool based on artificial intelligence). The developed diagnostic tool will make it possible to make allergy diagnoses based on blood test results faster, easier and without missing important information (eliminating the human factor as far as possible).

UAB "Imunodiagnostika" is implementing the project "Innovative tools for allergy diagnostics and treatment" (project No. J05-LVPA-K-03-0086) under the implementation measure No. J05-LVPA-K "Intellect. Joint science-business projects", which is funded by the European Regional Development Fund. The aim of the project is to develop a globally innovative product of biotechnological commercial value - recombinant proteins with diagnostic reagent properties. The project will add new equipment to the company's existing infrastructure for research and product development. The recombinant proteins/allergens to be developed under the project will meet the rapidly changing market realities:

• The developed technology will allow economical and standardized production of large quantities of recombinant allergens, which will be superior to those produced by other methods.

• The development of highly immunoreactive recombinant allergens would significantly improve the sensitivity and specificity of diagnostic tests;

• Recombinant allergens / proteins produced in the plant system would replace native allergen proteins in immunotherapy

UAB "Imunodiagnostika" is implementing the project "UAB "Imunodiagnostika" investments in R&D: innovations in allergy diagnostics" (project No. J05-LVPA-K-01-0155) under the measure No. J05-LVPA-K "Intellect. Joint Science-Business Projects", which is financed by the European Regional Development Fund (project budget - EUR 1 338 082,85, allocated funding - EUR 741 627,86). The main objective of the project is to carry out R&D activities to develop prototypes of two diagnostic kits based on an innovative microgrocket technology:

- Type I hypersensitivity to drugs;

- For the detection of type I hypersensitivity, inhalable and household allergens;

During the project, the equipment necessary for the implementation of the R&D activities of the project is also purchased - a micro grid spotter.